{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:28:58Z","timestamp":1787498938748,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T03:12:36Z","timestamp":1705806756000},"page":"566-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6939-039X","authenticated-orcid":false,"given":"Alan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2027-2437","authenticated-orcid":false,"given":"Harold","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benson","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul M.","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2024.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2024.01.001_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.01.001_bib0004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic Fibrosis","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jcf.2024.01.001_bib0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis and at least one","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jcf.2024.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis Heterozygous for","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.001_bib0007","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.001_bib0008","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.01.001_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-022-00687-0","article-title":"State of the Art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.jcf.2024.01.001_bib0010","unstructured":"Multi-discipline review, elexacaftor\/tezacaftor\/ivacaftor: US food and drug administration: center for drug evaluation and research; 2019 [Available from: https:\/\/www-accessdata-fda-gov.libproxy2.usc.edu\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf."},{"issue":"4","key":"10.1016\/j.jcf.2024.01.001_bib0011","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acs.chemrestox.7b00025","article-title":"Evaluation of DILI predictive hypotheses in early drug development","volume":"30","author":"Chan","year":"2017","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jcf.2024.01.001_bib0012","series-title":"Challenging Cases in Patients with Bronchiectasis. American Thoracic Society International Conference Abstracts","article-title":"Acute liver failure in a patient with Cystic Fibrosis taking triple combination modulator","author":"Sharma","year":"2021"},{"key":"10.1016\/j.jcf.2024.01.001_bib0013","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"10.1016\/j.jcf.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.jcf.2021.05.008","article-title":"Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis","volume":"21","author":"Smith","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.001_bib0015","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcf.2024.01.001_bib0016","unstructured":"FDA adverse event reporting system (FAERS) quarterly data extract files [Internet]. U.S. food and drug administration. 2023. Available from: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"10.1016\/j.jcf.2024.01.001_bib0017","unstructured":"Questions and answers on FDA's adverse event reporting system (FAERS): U.S. food and drug administration; 2018 [Available from: https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"key":"10.1016\/j.jcf.2024.01.001_bib0018","unstructured":"Instructions for Completing Form FDA 3500: U.S. food and drug administration; 2022 [Available from: https:\/\/www.fda.gov\/safety\/medwatch-forms-fda-safety-reporting\/instructions-completing-form-fda-3500#B2."},{"key":"10.1016\/j.jcf.2024.01.001_bib0019","doi-asserted-by":"crossref","unstructured":"Berthold MR, Cebron N, Dill F, Gabriel TR, K\u00f6tter T, Meinl T, et\u00a0al., editors. KNIME: The konstanz information miner2008; Berlin, Heidelberg: Springer Berlin Heidelberg.","DOI":"10.1007\/978-3-540-78246-9_38"},{"issue":"3","key":"10.1016\/j.jcf.2024.01.001_bib0020","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jcf.2024.01.001_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1044744","article-title":"Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.001_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050645","article-title":"Liver Injury with Nintedanib: a Pharmacovigilance-pharmacokinetic appraisal","volume":"15","author":"Raschi","year":"2022","journal-title":"Pharmaceuticals (Basel)."},{"issue":"6","key":"10.1016\/j.jcf.2024.01.001_bib0023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcf.2024.01.001_bib0024","series-title":"Data mining applications in engineering and medicine","first-page":"12","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012"},{"issue":"9","key":"10.1016\/j.jcf.2024.01.001_bib0025","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/0960327113512860","article-title":"Female gender as a susceptibility factor for drug-induced liver injury","volume":"33","author":"Amacher","year":"2014","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.jcf.2024.01.001_bib0026","series-title":"Trikafta package insert","year":"2023"},{"issue":"12","key":"10.1016\/j.jcf.2024.01.001_bib0027","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"10.1016\/j.jcf.2024.01.001_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071335","article-title":"Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury","volume":"18","author":"McEuen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.01.001_bib0029","unstructured":"Duggirala H.J., Tonning J.M., Smith E., Bright R.A., Baker J.D., Ball R., et\u00a0al. Data mining at FDA \u2013 white paper: US food and drug administration; 2018."},{"key":"10.1016\/j.jcf.2024.01.001_bib0030","article-title":"Adverse events of SARS-CoV-2 therapy: a pharmacovigilance study of the FAERS database","author":"Pannu","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.jcf.2024.01.001_bib0031","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s11096-020-01037-w","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system","volume":"42","author":"Lu","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"38","key":"10.1016\/j.jcf.2024.01.001_bib0032","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.2174\/0929867326666190409141016","article-title":"Ligand- and structure-based drug design and optimization using KNIME","volume":"27","author":"Mazanetz","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jcf.2024.01.001_bib0033","doi-asserted-by":"crossref","first-page":"e3138","DOI":"10.7717\/peerj.3138","article-title":"SLIMM: species level identification of microorganisms from metagenomes","volume":"5","author":"Dadi","year":"2017","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.jcf.2024.01.001_bib0034","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:31:32Z","timestamp":1777649492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000018"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}